GGrantIndex
← Leaderboards

Lary C Walker

Emory University

Google Scholar ↗PubMed ↗ORCID ↗
$2,229,350
Attributed
$2,563,546
Total exposure
18
Grants
15
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $493.5K · FY2005–19
$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19

Funding mix

By agency

NIH$2,563,546 · 18

By mechanism

P50$1,042,517 · 1
R21$873,280 · 2
P51$444,115 · 14
RF1$203,634 · 1

Top collaborators

Most similar at Emory University

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos”

Research focus

Alzheimer&AposS DiseaseBrainUnited States National Institutes Of HealthProteinsFundingResearch PersonnelPrimatesResourcesSourcePathologyGrantPathogenesisInstitutionIn VivoComputer Retrieval Of Information On Scientific Projects DatabaseNonhuman PrimatePathologicMouse ModelCellsSaimiriSeedsMolecularLink

Grant awards (24)

Defining the Properties of Pathogenic A-beta strains in AD$226,832
P50 · FY2019 · AG · contact PI
Defining the Properties of Pathogenic A-beta strains in AD$234,399
P50 · FY2018 · AG · contact PI
Inflammation and Renin-Angiotensin System Dysfunction as risk factors for AD$203,634
RF1 · FY2017 · AG
Defining the Properties of Pathogenic A-beta strains in AD$194,983
P50 · FY2017 · AG · contact PI
Defining the Properties of Pathogenic A-beta strains in AD$184,769
P50 · FY2016 · AG · contact PI
Defining the Properties of Pathogenic A-beta strains in AD$201,534
P50 · FY2015 · AG · contact PI
Cerebral small vessel disease: Enhancing the diagnostic precision of MRI$220,000
R21 · FY2012 · NS · contact PI
Cellular trafficking of pathogenic Abeta seeds in vitro and in vivo$180,400
R21 · FY2012 · AG · contact PI
Cerebral small vessel disease: Enhancing the diagnostic precision of MRI$256,400
R21 · FY2011 · NS · contact PI
Cellular trafficking of pathogenic Abeta seeds in vitro and in vivo$216,480
R21 · FY2011 · AG · contact PI
ALZHEIMER'S DISEASE: MODELING PATHOLOGIC STRAIN-LIKE VARIANTS OF MULTIMERIC A?$20,580
P51 · FY2011 · RR · contact PI
ALZHEIMER'S DISEASE: MODELING PATHOLOGIC STRAIN-LIKE VARIANTS OF MULTIMERIC A?$27,414
P51 · FY2010 · RR · contact PI
ALZHEIMER'S DISEASE: MODELING PATHOLOGIC STRAIN-LIKE VARIANTS OF MULTIMERIC A?$27,456
P51 · FY2009 · RR · contact PI
TRANSGENIC EXPRESSION OF TAU AND APP IN MODELS OF ALZHEIMER'S DISEASE$35,600
P51 · FY2008 · RR · contact PI
EXOGENOUS INDUCTION OF ALZHEIMER A?-PATHOLOGY IN TRANSGENIC MICE$28,536
P51 · FY2008 · RR · contact PI
ALZHEIMER'S IMMUNOTHERAPY IN A PRIMATE MODEL OF CEREBRAL AMYLOID ANGIOPATHY$28,536
P51 · FY2008 · RR · contact PI
BIOMARKERS BRAIN PATHOLOGY: RISKS FOR ALZHEIMER?S DISEASE AND DRUG ADDICTION$28,536
P51 · FY2008 · RR · contact PI
TRANSGENIC EXPRESSION OF TAU AND APP IN MODELS OF ALZHEIMER'S DISEASE$39,499
P51 · FY2007 · RR · contact PI
ALZHEIMER'S IMMUNOTHERAPY IN A PRIMATE MODEL OF CEREBRAL AMYLOID ANGIOPATHY$39,499
P51 · FY2007 · RR · contact PI
BIOMARKERS BRAIN PATHOLOGY: RISKS FOR ALZHEIMER?S DISEASE AND DRUG ADDICTION$31,600
P51 · FY2007 · RR · contact PI
LENTIVIRAL-MEDIATED EXPRESSION OF TRANSGENIC BETA-APP AND PRESENILIN IN MONKEYS$31,598
P51 · FY2007 · RR · contact PI
LENTIVIRAL-MEDIATED EXPRESSION OF TRANSGENIC BETA-APP AND PRESENILIN IN MONKEYS$40,116
P51 · FY2006 · RR · contact PI
LENTIVIRAL-MEDIATED EXPRESSION OF TRANSGENIC BETA-APP AND PRESENILIN IN MONKEYS$30,784
P51 · FY2005 · RR
A NEW MODEL OF ALZHEIMER'S DISEASE PATHOGENESIS$34,361
P51 · FY2004 · RR